Article Text

Download PDFPDF
Lessons from type I interferons in ulcerative colitis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Linked articles 226860.

  • Funding The authors' laboratories are supported by NIH RO1 grants DK44319, DK51362, DK53056 and DK08819 (RSB), T32 DK07533-21A1 (RSB) and P30 DK034854 (Harvard Digestive Diseases Center), European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no. 260961 (AK), the Austrian Science Fund and Ministry of Science P21530 (AK) and START Y446 (AK), and the National Institute for Health Research Cambridge Biomedical Research Centre (AK). RSB is listed as co-inventor on a patent involving IL-13 targeting for the treatment of UC.

  • Competing interests None.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles